**Supplementary Material**

**Table 1.** Correlation between T:R ratios in anterior and inferior leads and basic demographic and clinical characteristics of our study population.

|  |  |  |
| --- | --- | --- |
|  | T:R anterior | T:R inferior |
|  | p-value | Correlation coefficient | p-value | Correlation coefficient |
| Sex, n (men/women), (%) | 0.24 |  0.100 | 0.68 | -0.036 |
| Age, yr | 0.15 |  0.084 | 0.04 |  0.123 |
| Body Mass index, (kg/m²) | 0.38 |  0.051 | 0.57 |  0.033 |
| Smokers, n (%) Current smokers, n (%) Previous smokers, n (%) | 0.110.40 |  0.138-0.073 | 0.610.77 | -0.044 0.025 |
| Previous diagnosis, n (%) Diabetes mellitus 1 or 2 CAD NSTEMI Coronary stent implantation Coronary artery bypass Peripheral artery occlusive disease Prior stroke Cardiac defect Cardiac arrhythmia Congestive heart failure Left ventricular hypertrophy | 0.200.780.250.810.620.140.100.340.340.510.71 |  0.108-0.024 0.098-0.020 0.043 0.125 0.142-0.082 0.082 0.056-0.031 | 0.580.730.960.780.910.820.800.890.100.450.69 |  0.048 0.030-0.005 0.024 0.010 0.019-0.022-0.012-0.140 0.065-0.035 |
| Cause of ERSD, n (%) Diabetic nephropathy Hypertensive nephroslerosis Glomerulonephritis Interstitial nephritis Polycystic kidney disease Hereditary Unknown Others | 0.080.380.260.310.530.850.330.59 |  0.149 0.075-0.097-0.086 0.053 0.016-0.083 0.046 | 0.470.870.550.970.880.830.860.70 |  0.062 0.014-0.051-0.003-0.013 0.018-0.015 0.033 |
| Medications, n (%) ACE inhibitor ß-Blocker Angiotensin II-receptor antagonist Calcium channel blocker Sympatholytics Diuretic Cinalcalcet Vitamin D Phenprocoumon ASS Erythropoetin Statin Allopurinol | 0.410.520.460.210.320.980.0040.340.920.970.240.400.97 | -0.071 0.055-0.063 0.107 0.085 0.002 0.242-0.081-0.009-0.004-0.101-0.072 0.003 | 0.040.190.470.810.420.120.780.200.910.950.300.330.22 | -0.180-0.113-0.062-0.020-0.068-0.134 0.024 0.109 0.010-0.005 0.088-0.083-0.106 |
| Laboratory values of the day of listing eGFR (CKD-Epi), ml/min Sodium, mmol/l Potassium, mmol/l Calcium, mmol/l Total Protein, g/l Albumin, % Phosphorus, mmol/l Alkaline Phosphatase, U/l Triglycerides, mg/dl Cholesterol, mg/dl HDL, mg/dl LDL, mg/dl Glucose, mg/dl HbA1c, % Uric acid, mg/dl Leukocytes, G/l Hemoglobin, g/dl Thrombocytes, G/l Prothrombin time, % PTT, sec AT, % Fibrinogen, mg/dlFurther laboratory variables eGFR (CKD-Epi) day of discharge after transplantation, ml/min eGFR (CKD-Epi) 1-year follow up,  ml/min | 0.080.830.0060.970.010.470.040.260.050.460.520.170.330.030.160.790.0030.490.470.760.210.680.570.77 | -0.103-0.013 0.163-0.002 0.148-0.043 0.118-0.065-0.112-0.043 0.042-0.089 0.057 0.129-0.082 0.015 0.174 0.040 0.049-0.019-0.079 0.026-0.034-0.018 | 0.070.760.100.670.620.280.150.680.490.360.090.760.770.960.400.280.610.550.460.630.060.870.350.39 | -0.106-0.018 0.097-0.025-0.029 0.065 0.083-0.024-0.040 0.053 0.112-0.020-0.017-0.003-0.049-0.063 0.030-0.035 0.050-0.030-0.118-0.010-0.055-0.051 |
| Previous kidney transplant, n (%) | 0.19 |  0.112 | 0.37 | -0.077 |
| Dialysis-related information CAPD, n (%) HD, n (%) Duration of dialysis, hr/wk Diuresis on day of listing, ml Frequency of dialysis, d/wk | 0.020.020.560.660.60 | -0.204 0.209 0.042-0.026-0.041 | 0.940.740.790.750.37 |  0.007 0.028 0.020-0.019 0.071 |
| Transplantation-related information Time to transplantation, yr Diuresis before transplantation, ml | 0.870.91 |  0.010 0.007 | 0.400.21 |  0.049-0.075 |

CAD, coronary artery disease; NSTEMI, non ST elevation myocardial infarction; ACE inhibitor, angiotensin-converting enzyme inhibitor; PTT, partial thromboplastin time; AT, antithrombin; CAPD, continuously ambulatory peritoneal disease; HD, hemodialysis.